# Nuwellis Forms Pediatric Advisory Board to Guide Vivian CRRT Development

- URL: https://stocks.freetheai.org/news/nuwellis-forms-pediatric-advisory-board-to-guide-vivian-crrt-development-590120
- Published: 2026-10-08T12:30:00Z
- Category: company_news; sentiment: neutral; impact: low
- Symbols: [NASDAQ:NUWE](https://stocks.freetheai.org/symbols/NASDAQ-NUWE)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Nuwellis, Inc. (NASDAQ:NUWE) has announced it will convene a Pediatric Medical & Nursing Advisory Board on Nov. 18–19, 2026. The board is tasked with guiding the development of the company's Vivian pediatric continuous renal replacement therapy (CRRT) platform, which is designed to treat patients weighing as little as 2.5 kilograms.

The initiative is part of a broader pediatric growth strategy for the medical technology firm. Alongside the Vivian platform, the company is seeking a regulatory label expansion for its existing Aquadex system. The proposed change aims to allow the use of Aquadex on patients weighing 5 kilograms or more, expanding its current limit of 20 kilograms or more.

During the upcoming meeting, approximately 12 clinicians will perform a hands-on evaluation of the Vivian platform to refine its features and design. Investors will likely watch for regulatory progress on the Aquadex label expansion and further updates regarding the development timeline and clinical testing of the Vivian platform.

## Key points

- Nuwellis, Inc. will host a Pediatric Medical & Nursing Advisory Board on Nov. 18–19, 2026.
- The advisory board will guide development of the Vivian pediatric CRRT platform, targeting infants as small as 2.5 kg.
- The company is also pursuing an Aquadex label expansion to treat patients weighing 5 kg or more, down from the current 20 kg limit.
- Around 12 clinicians will conduct hands-on evaluations to validate and refine the Vivian system design.

## Questions and answers

### What is the purpose of the new Nuwellis pediatric advisory board?

The board will meet on Nov. 18–19, 2026, to guide the development of the Vivian pediatric CRRT platform and evaluate its features.

### What patients does the Vivian pediatric CRRT platform target?

The Vivian platform is designed to provide continuous renal replacement therapy for pediatric patients weighing as little as 2.5 kilograms.

### What is Nuwellis proposing for its Aquadex system?

Nuwellis is seeking a regulatory label expansion to allow the Aquadex system to be used on patients weighing 5 kilograms or more, lowering the current limit from 20 kilograms.